Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

CellProtect (ex vivo expanded and activated autologous natural killer cells) - Avaris, CellProtect Nordic Pharma

Sarclisa (isatuximab-irfc) - Sanofi

http://clinicaltrials.gov/ct2/show/NCT04558931

Sep 22, 2020